FDA Lays Out Weight of Evidence Guidelines for Fetal Toxicity in Oncology

Drug Industry Daily
Cancer drug sponsors won’t have to do separate studies if they can demonstrate that the weight of evidence shows that a given drug is dangerous to developing babies, the FDA says in a final guidance document issued Thursday.

To View This Article:


Subscribe To Drug Industry Daily